UPDATE 1-Johnson & Johnson to buy Actelion for $30 bln

ZURICH, Jan 26 (Reuters) - Swiss biotech company Actelion

said on Thursday it had agreed to be purchased by

Johnson & Johnson in a $30 billion all-cash deal,

following weeks of speculation a deal was imminent.

Read more